Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression

Gastroenterology. 1999 Aug;117(2):327-35. doi: 10.1053/gast.1999.0029900327.

Abstract

Background & aims: Maintenance of normal epithelial differentiation and proliferation is an important goal in cancer chemoprevention. Because acid has a dynamic effect on cell proliferation/differentiation of Barrett's esophagus (BE) ex vivo, we investigated the relationship between differentiation, proliferation, and dysplasia in BE biopsy specimens and explored the role of normalization of intraesophageal pH in altering the BE phenotype.

Methods: Endoscopic biopsy specimens of BE (with or without dysplasia) were analyzed for (1) villin, a differentiation marker, by immunoblotting; (2) proliferating cell nuclear antigen (PCNA), a proliferation marker, by immunohistochemistry; and (3) dysplasia by histology before and after 6 months of normalization of intraesophageal pH (confirmed by 24-hour pH monitoring) with lansoprazole.

Results: At baseline, there was a negative correlation (r = -0.79) between villin and PCNA expression. Six months later, PCNA expression decreased and villin expression increased (P < 0.001) in 24 patients whose intraesophageal pH normalized. Fifteen patients had persistently pathological intraesophageal acid reflux and no change in villin or PCNA expression. There were no differences in the occurrence of dysplasia after 6 months in either group.

Conclusions: In BE, there is an inverse relationship between villin and PCNA. In turn, dysplasia is unrelated to villin expression and well correlated with PCNA expression. Complete symptom eradication with lansoprazole does not guarantee normalization of intraesophageal pH profile in BE patients. Effective intraesophageal acid suppression favors differentiation and decreases proliferation. The intriguing possibility that acid suppression can be used to prevent dysplasia remains to be explored.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Ulcer Agents / therapeutic use*
  • Barrett Esophagus / drug therapy*
  • Barrett Esophagus / metabolism
  • Barrett Esophagus / pathology
  • Carrier Proteins / analysis
  • Cell Differentiation / drug effects
  • Cell Division / drug effects
  • Female
  • Gastric Acid / metabolism*
  • Humans
  • Hydrogen-Ion Concentration
  • Immunoblotting
  • Immunohistochemistry
  • Lansoprazole
  • Male
  • Microfilament Proteins / analysis
  • Middle Aged
  • Omeprazole / analogs & derivatives*
  • Omeprazole / therapeutic use
  • Proliferating Cell Nuclear Antigen / analysis

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Carrier Proteins
  • Microfilament Proteins
  • Proliferating Cell Nuclear Antigen
  • villin
  • Lansoprazole
  • Omeprazole